Ranibizumab: Uses, Side Effects, and Injection Process

Ranibizumab is an injectable medication designed to treat several serious eye conditions by blocking the protein that drives abnormal blood vessel growth and leakage in the retina. Approved under the brand name Lucentis, it is given as a tiny injection directly into the eye and has become one of the most widely used treatments for wet age-related macular degeneration (AMD), diabetic macular edema, and related retinal diseases. The drug works well for most patients, but staying on treatment requires regular visits and repeat injections that many people find daunting.

How Ranibizumab Works

The retina depends on a healthy blood supply, but in certain diseases the body produces too much of a signaling protein called vascular endothelial growth factor, or VEGF. Excess VEGF triggers new, fragile blood vessels to sprout and existing vessels to leak fluid into the retina, distorting or destroying central vision. Ranibizumab is a small antibody fragment engineered to latch onto VEGF-A and neutralize it. Lab studies show it binds to three biologically active forms of VEGF-A and blocks them in a dose-dependent way, effectively shutting down the signal that causes vessels to leak and grow where they shouldn’t.¹ More recent biophysical measurements have confirmed the drug binds VEGF extremely tightly, with a residence time of about 19 days, meaning once ranibizumab grabs hold of VEGF inside the eye, it stays attached for a long while before letting go.²

Because ranibizumab is a small fragment rather than a full-size antibody, it penetrates the layers of the retina more easily after injection. By reducing VEGF levels in the eye, the drug helps seal leaking vessels, prevents new abnormal vessels from forming, and allows the retina’s own structural barriers to recover. Research on diabetic macular edema has shown that anti-VEGF treatment can restore the external limiting membrane of the retina, a crucial barrier that, once intact, helps the deeper photoreceptor layer heal as well.³

Conditions Ranibizumab Treats

Ranibizumab is approved for several retinal diseases that share the common thread of VEGF-driven damage. Understanding which conditions respond, and how well, helps explain why this drug has become a cornerstone of retinal care.

Wet Age-Related Macular Degeneration

Wet AMD is the condition ranibizumab was originally developed to treat. In this disease, abnormal blood vessels grow beneath the macula and leak fluid, causing rapid central vision loss. Clinical data consistently show that ranibizumab stabilizes or improves vision in a large majority of patients. In one 12-month study, about 92% of treated eyes either held steady or gained vision, with a mean improvement of roughly 11 letters on a standard eye chart.⁴ Longer-term data tell a more nuanced story. A three-year study found that vision improved significantly in the first year but tended to drift back toward baseline over the following two years. Patients who received seven or more injections over that period fared substantially better at maintaining their gains than those who received fewer treatments.⁵

Real-world results, outside the carefully controlled setting of clinical trials, tend to be more modest. A multicenter study following over 550 patients treated by 16 different ophthalmologists found an average gain of only about 3 letters at 12 months, partly because not all patients received the full recommended loading doses or were treated quickly enough.⁶ Prompt initiation of treatment made a measurable difference in that study, a finding that reinforces the importance of acting quickly when wet AMD is diagnosed.

Diabetic Macular Edema

Diabetic macular edema (DME) occurs when diabetes-related vessel damage causes fluid to accumulate in the central retina. The landmark RISE and RIDE trials established that ranibizumab reduces macular swelling and is less likely to allow diabetic retinopathy to worsen compared with sham treatment.⁷ A head-to-head comparison of three anti-VEGF drugs for DME found that ranibizumab improved vision by an average of about 11 letters over one year. When patients started with worse vision, aflibercept showed a larger advantage, but for patients whose vision was only mildly reduced at baseline, the three drugs performed similarly.⁸

Retinal Vein Occlusion

When a vein draining the retina becomes blocked, fluid backs up and the macula swells. The BRAVO trial showed that patients with branch retinal vein occlusion treated with ranibizumab gained an average of about 18 letters at one year, and roughly 60% gained 15 letters or more, a threshold considered clinically meaningful.⁹ Japanese data suggest some patients may need fewer injections than those pivotal trials implied, with one study reporting a 22-letter gain using an average of only about four injections over a year.¹⁰

Retinopathy of Prematurity

Ranibizumab is also used in very young patients. Retinopathy of prematurity (ROP) affects premature infants whose retinal blood vessels have not finished developing. The RAINBOW trial compared ranibizumab to laser therapy and found a treatment success rate of 80% with the higher ranibizumab dose versus 66% with laser. Structural outcomes were also better, with only one infant in the ranibizumab group experiencing an unfavorable structural result compared with seven in the laser group.¹¹

What the Injection Is Actually Like

The idea of a needle in the eye understandably alarms people, and injection-related anxiety is one of the main reasons patients skip or delay treatment.¹² In practice, the procedure is quick and usually less painful than expected. Here is what typically happens:

Numbing: The eye is anesthetized with drops or a small gel, so you should not feel sharp pain during the injection itself.
Sterilization: Povidone-iodine (a brown antiseptic) is applied to the eye surface and lids to minimize infection risk. A small speculum holds your eyelids open.
Injection: A very fine needle is inserted through the white of the eye (the sclera), a few millimeters behind the corneal edge, into the vitreous gel. The entire injection takes only a few seconds.
Aftercare: The speculum is removed, the eye is usually rinsed, and you are observed briefly before going home. Most people can resume normal activities the same day.

Immediately after the injection, eye pressure spikes because extra fluid has been added to a closed space. Studies tracking this spike show that pressure typically starts high and drops substantially within about 30 minutes.¹³ One factor that influences how high the spike goes is whether any vitreous gel refluxes back through the needle track. When more fluid escapes immediately after the needle is withdrawn, the pressure jump tends to be smaller.¹⁴ For most people this transient spike is harmless, but patients who already have glaucoma or borderline-high eye pressure need closer monitoring. A study of over 100 eyes found that sustained pressure elevation occurred in about 7.5% of eyes receiving ranibizumab, and those with pre-existing glaucoma were more likely to be affected.¹⁵

Side Effects and Safety Profile

The most common side effects are local. Bloodshot eye (subconjunctival hemorrhage), mild soreness, and floaters are frequent and generally resolve within days. Eye inflammation and temporary blurry vision also occur but usually settle quickly.

The serious complication clinicians worry about most is endophthalmitis, a bacterial infection inside the eye. A large safety review of over 38,500 ranibizumab injections found an endophthalmitis rate of about 0.036%, or roughly one case per 2,750 injections. Of those 14 cases, half turned out to be linked to a brief period when faulty needles required replacement in the operating room, suggesting that strict procedural protocols keep the baseline risk even lower.¹⁶ Other rare serious events in that study included retinal detachment and traumatic cataract, each occurring in a single eye out of the entire cohort.

Because VEGF plays roles outside the eye, including in blood vessel maintenance throughout the body, there has been concern about systemic cardiovascular side effects. Large-scale data are reassuring. A nationwide cohort study of over 250,000 patients found no increased risk of heart attack, stroke, or death when comparing ranibizumab users to those receiving aflibercept.¹⁷ Separate analyses comparing ranibizumab and bevacizumab found similarly low systemic event rates, with no statistically significant difference between the drugs for heart attack, stroke, major bleeding, or hospitalization.¹⁸ A smaller study reported overall systemic adverse events in about 1.5% of ranibizumab patients, comparable to the rate in bevacizumab patients.¹⁹

How Treatment Schedules Work

Ranibizumab is not a one-time injection. Most patients start with three monthly loading doses, then continue with ongoing treatment whose frequency depends on their response. Two main scheduling strategies dominate practice, and which one your doctor uses matters for outcomes.

In the “pro re nata” (PRN) or as-needed approach, you get an injection only when imaging or a vision test shows the disease is active again. This means fewer injections but more monitoring visits and a risk that the disease flares between treatments. In the “treat-and-extend” (T&E) approach, you get an injection at every visit, but the interval between visits is gradually stretched as long as the eye remains stable. If the disease recurs, the interval is shortened.

A systematic review and meta-analysis found that treat-and-extend delivered similar vision gains to monthly injections at 12 months, with about 1.6 fewer injections per year. Compared with as-needed dosing, treat-and-extend produced a meaningful advantage of roughly six extra letters of vision, though it required about 1.4 more injections per year.²⁰ A real-world comparative study in wet AMD patients echoed this pattern: at two years, treat-and-extend patients gained about four letters on average versus just one letter in the as-needed group, with about five more injections over that time.²¹

For diabetic macular edema specifically, the treat-and-extend advantage appeared even more pronounced. A two-year study showed patients on treat-and-extend gained about 16 letters versus about 8 letters for as-needed patients. Recurrence of macular edema was also lower in the treat-and-extend group (41% versus 71%), which likely explains part of the vision gap.²²

How Ranibizumab Compares to Other Anti-VEGF Drugs

Ranibizumab is not the only anti-VEGF option. Bevacizumab (Avastin) and aflibercept (Eylea) are used for many of the same conditions, and patients often hear about all three. A large head-to-head trial for diabetic macular edema found that all three improved vision, but aflibercept led by a small margin overall, gaining about 13 letters versus 11 for ranibizumab and 10 for bevacizumab. The gap was more relevant for patients whose starting vision was worse; among those with milder impairment, the drugs performed similarly.²³

A practical difference is cost. Bevacizumab is dramatically cheaper because it is used off-label (it was developed as a cancer drug and is repackaged in smaller doses for the eye). Ranibizumab is typically far more expensive per injection. This cost difference drives real-world prescribing patterns, especially in healthcare systems with limited budgets, and has spurred the development of ranibizumab biosimilars aimed at closing the price gap.

Biosimilars and Access

Several ranibizumab biosimilars have reached the market or are in late-stage development. Byooviz (SB11) was one of the first. A post-hoc analysis of its phase 3 trial found that it matched reference ranibizumab in visual acuity gains, with anti-drug antibody formation occurring in only about 5% of participants, and those antibodies did not appear to affect how well the drug worked or its safety profile.²⁴ Another biosimilar, QL1205, demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics to reference ranibizumab in a separate phase 3 trial.²⁵ A broader meta-analysis looking across multiple ranibizumab biosimilar trials confirmed low rates of anti-drug antibody formation with no measurable impact on outcomes.²⁶

Biosimilars matter because the high cost of brand-name biologics can lead to underuse and, consequently, worse vision outcomes for patients who cannot access or afford sufficient treatment. Lowering the per-injection price could make it easier for patients and healthcare systems to stay on the recommended dosing schedule rather than stretching intervals further than ideal or switching to less-studied alternatives out of financial necessity.

The Port Delivery System

Even with treat-and-extend scheduling, many patients need injections every one to three months for years. The Port Delivery System (PDS) represents a fundamentally different approach: a tiny refillable implant surgically placed in the eye wall that continuously releases a concentrated form of ranibizumab into the vitreous for about six months between refills.²⁷

The two-year results of the Archway phase 3 trial showed that PDS refilled every six months was noninferior to monthly ranibizumab injections for wet AMD, with comparable vision and anatomic outcomes through 96 weeks. Over 94% of patients did not need any supplemental injections between refills. The tradeoff is that PDS requires a one-time surgical procedure to implant the device, and the implant carries its own set of risks. About 24% of PDS patients experienced at least one prespecified adverse event of special interest, including conjunctival erosion, conjunctival retraction, and uncommon but serious events like endophthalmitis and implant dislocation.²⁸

A meta-analysis also evaluated PDS in diabetic eye disease, finding it noninferior to monthly ranibizumab for DME and showing strong improvement in diabetic retinopathy severity in patients without center-involved swelling. Supplemental treatment was needed in only about 3% of participants, and no cases of endophthalmitis were reported in the diabetic trials specifically.²⁹ For patients who struggle with the burden of frequent office visits, PDS could be a meaningful improvement in quality of life, though the implant procedure itself and its unique complications mean it is not the right fit for everyone.

Why People Stop Treatment and What Helps

Treatment with ranibizumab is often open-ended, and that creates a real adherence problem. A systematic review of intravitreal treatment found that the high burden of follow-up visits, anxiety and fear related to the injections, disappointed expectations when vision did not improve as much as hoped, and loss of motivation over time were all common reasons patients dropped out.³⁰

About half of patients in one study reported moderate to severe anxiety during injections, and roughly one in five felt their treatment was not working, despite objective imaging often showing improvement.³¹ That disconnect between what the scans show and what patients feel is worth understanding. These drugs often stabilize or slowly improve the structural health of the retina in ways that do not immediately translate into noticeably sharper vision for the patient. When someone expects to read finer print after treatment and instead finds their vision roughly the same, it is easy to conclude the injections are not worth the trouble. Having a candid conversation with your retina specialist about what “success” looks like, which is often preventing further loss rather than dramatic recovery, can help recalibrate expectations.

Practical strategies that help people stay on track include coordinating appointments with a regular companion who provides transportation, asking about topical anesthetic techniques that minimize discomfort, and discussing treat-and-extend scheduling that may reduce total visit numbers compared with monthly monitoring. For patients with severe needle anxiety, some clinics offer distraction techniques or pre-procedure anxiolytics. The emerging option of the Port Delivery System, which cuts visit frequency to twice a year, is another solution for those who find the monthly or bimonthly cadence unsustainable.